What's New With TMS for Depression:

What's New With TMS for Depression:

20+ Years since Proof of Concept & 8 Years after FDA Approval

This Grand Rounds webinar will:

• Discuss the latest TMS studies and research findings
• Provide a better understanding of when you can deviate from FDA approved TMS treatment doses
• Review evidence which supports potential deviations from FDA approved doses

Date: Tuesday, February 7, 2017

Time: 8:00pm (EST) / 5:00pm (PST) 

Format: Webinar using Zoom Video Communications

Cost: Members: $25 | Non-members: $50

Speaker: Mark S. George, MD

As an undergraduate student in philosophy at Davidson College in Davidson, NC, Dr. George first began studying the relationship between mind and brain, or brain/behavior relationships.  He has continued this interest throughout his career with a focus on using brain imaging and brain stimulation to understand depression and devise new treatments.

He received his medical degree from the Medical University of South Carolina in Charleston in 1985, where he continued with dual residencies in both neurology and psychiatry. He is board certified in both areas. Following his residency training he worked for one year (1990-91) as a Visiting Research Fellow in the Raymond Way Neuropsychiatry Research Group at the Institute of Neurology, Queen Square, London, England. He then moved to Washington, DC, working with Dr. Robert Post in the Biological Psychiatry Branch of the Intramural National Institute of Mental Health (NIMH).  During his 4 years at NIMH he was one of the first to use functional imaging (particularly oxygen PET) and discovered that specific brain regions change activity during normal emotions. He then started using imaging to understand brain changes that occur in depression and mania, a quest that he and many others are still pursuing. This imaging work directly led to his pioneering use of a non-invasive brain stimulation method, transcranial magnetic stimulation (TMS), as a probe of neuronal circuits regulating mood, and to clinical trials using TMS as an antidepressant. In 1993 while at the NIMH, he discovered that daily prefrontal rTMS over several weeks could treat depression and ever since he has worked to grow the science of TMS, both in terms of how it works in the brain, and in critically evaluating its therapeutic applications, especially in the area of treating depression. In June 1998 at MUSC, he also helped pioneer another new treatment for resistant depression, vagus nerve stimulation (VNS). This was FDA approved in 2006. He and his group have used MRI imaging to understand VNS brain effects.

He is a world expert in brain stimulation, and depression, and is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has been continuously funded by NIH and other funding agencies since his fellowships. He has received both a NARSAD Young Investigator and Independent Investigator Award to pursue TMS research in depression. He has received numerous international awards including the NARSAD Klerman Award (2000), NARSAD Falcone Award (2008) and the Lifetime Achievement Award (2007) given by the World Federation of Societies of Biological Psychiatry (WFSBP). In 2009 US News and World Report named him one of 14 ‘medical pioneers who are not holding back’. He is on several editorial review boards and NIH study sections, has published over 400 scientific articles or book chapters, and has written or edited 6 books.